Cargando…

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

BACKGROUND: The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. METHODS: We retrospectively analyzed data from breast cancer patients who began treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Huang, Xiang, Sun, Chunxiao, Li, Jianbin, Wang, Biyun, Yan, Min, Jin, Feng, Wang, Haibo, Zhang, Jin, Fu, Peifen, Zeng, Tianyu, Wang, Jian, Li, Wei, Li, Yongfei, Yang, Mengzhu, Li, Jun, Wu, Hao, Fu, Ziyi, Yin, Yongmei, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104485/
https://www.ncbi.nlm.nih.gov/pubmed/32223744
http://dx.doi.org/10.1186/s12885-020-6639-4
_version_ 1783512244392296448
author Yang, Fan
Huang, Xiang
Sun, Chunxiao
Li, Jianbin
Wang, Biyun
Yan, Min
Jin, Feng
Wang, Haibo
Zhang, Jin
Fu, Peifen
Zeng, Tianyu
Wang, Jian
Li, Wei
Li, Yongfei
Yang, Mengzhu
Li, Jun
Wu, Hao
Fu, Ziyi
Yin, Yongmei
Jiang, Zefei
author_facet Yang, Fan
Huang, Xiang
Sun, Chunxiao
Li, Jianbin
Wang, Biyun
Yan, Min
Jin, Feng
Wang, Haibo
Zhang, Jin
Fu, Peifen
Zeng, Tianyu
Wang, Jian
Li, Wei
Li, Yongfei
Yang, Mengzhu
Li, Jun
Wu, Hao
Fu, Ziyi
Yin, Yongmei
Jiang, Zefei
author_sort Yang, Fan
collection PubMed
description BACKGROUND: The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. METHODS: We retrospectively analyzed data from breast cancer patients who began treatment with regimens of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) at eight hospitals between May 2010 and October 2017. RESULTS: Among 554 patients who had developed resistance to trastuzumab, the median PFS (progression free survival) was 6.77 months in the LX group compared with 5.6 months in the TBP group (hazard ratio 0.804; 95% CI, 0.67 to 0.96; P = 0.019). The central nervous system progression rate during treatment was 5.9% in the LX group and 12.5% in the TBP group (P = 0.018). CONCLUSION: The combination of lapatinib and capecitabine showed a prolonged PFS relative to TBP in patients who had progressed on trastuzumab.
format Online
Article
Text
id pubmed-7104485
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71044852020-03-31 Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population Yang, Fan Huang, Xiang Sun, Chunxiao Li, Jianbin Wang, Biyun Yan, Min Jin, Feng Wang, Haibo Zhang, Jin Fu, Peifen Zeng, Tianyu Wang, Jian Li, Wei Li, Yongfei Yang, Mengzhu Li, Jun Wu, Hao Fu, Ziyi Yin, Yongmei Jiang, Zefei BMC Cancer Research Article BACKGROUND: The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. METHODS: We retrospectively analyzed data from breast cancer patients who began treatment with regimens of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) at eight hospitals between May 2010 and October 2017. RESULTS: Among 554 patients who had developed resistance to trastuzumab, the median PFS (progression free survival) was 6.77 months in the LX group compared with 5.6 months in the TBP group (hazard ratio 0.804; 95% CI, 0.67 to 0.96; P = 0.019). The central nervous system progression rate during treatment was 5.9% in the LX group and 12.5% in the TBP group (P = 0.018). CONCLUSION: The combination of lapatinib and capecitabine showed a prolonged PFS relative to TBP in patients who had progressed on trastuzumab. BioMed Central 2020-03-29 /pmc/articles/PMC7104485/ /pubmed/32223744 http://dx.doi.org/10.1186/s12885-020-6639-4 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yang, Fan
Huang, Xiang
Sun, Chunxiao
Li, Jianbin
Wang, Biyun
Yan, Min
Jin, Feng
Wang, Haibo
Zhang, Jin
Fu, Peifen
Zeng, Tianyu
Wang, Jian
Li, Wei
Li, Yongfei
Yang, Mengzhu
Li, Jun
Wu, Hao
Fu, Ziyi
Yin, Yongmei
Jiang, Zefei
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
title Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
title_full Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
title_fullStr Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
title_full_unstemmed Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
title_short Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
title_sort lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a chinese population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104485/
https://www.ncbi.nlm.nih.gov/pubmed/32223744
http://dx.doi.org/10.1186/s12885-020-6639-4
work_keys_str_mv AT yangfan lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT huangxiang lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT sunchunxiao lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT lijianbin lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT wangbiyun lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT yanmin lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT jinfeng lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT wanghaibo lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT zhangjin lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT fupeifen lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT zengtianyu lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT wangjian lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT liwei lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT liyongfei lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT yangmengzhu lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT lijun lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT wuhao lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT fuziyi lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT yinyongmei lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation
AT jiangzefei lapatinibincombinationwithcapecitabineversuscontinueduseoftrastuzumabinbreastcancerpatientswithtrastuzumabresistancearetrospectivestudyofachinesepopulation